123 related articles for article (PubMed ID: 29761420)
1. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
Strand V; Kavanaugh A; Kivitz AJ; van der Heijde D; Kwok K; Akylbekova E; Soonasra A; Snyder M; Connell C; Bananis E; Smolen JS
Rheumatol Ther; 2018 Dec; 5(2):341-353. PubMed ID: 29761420
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Strand V; Lee EB; Yazici Y; Dikranian A; Wilkinson B; Takiya L; Zang C; Bananis E; Bergman MJ
Clin Rheumatol; 2018 Aug; 37(8):2043-2053. PubMed ID: 29656373
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
Fleischmann R; Haraoui B; Buch MH; Gold D; Sawyerr G; Shi H; Diehl A; Lee K
Rheumatol Ther; 2023 Apr; 10(2):375-386. PubMed ID: 36534208
[TBL] [Abstract][Full Text] [Related]
5. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
Wright GC; Mysler E; Kwok K; Cadatal MJ; Germino R; Yndestad A; Kinch CD; Ogdie A
Rheumatol Ther; 2024 Jul; ():. PubMed ID: 38958913
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
[TBL] [Abstract][Full Text] [Related]
7. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention.
Pope J; Finckh A; Silva-Fernández L; Mandl P; Fan H; Rivas JL; Valderrama M; Montoro M
Open Access Rheumatol; 2024; 16():115-126. PubMed ID: 38883150
[TBL] [Abstract][Full Text] [Related]
9. Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.
Ciurea A; Distler O; Kwok K; Jo H; Wang L; Killeen T; Ospelt C; Frank Bertoncelj M
Arthritis Res Ther; 2023 Sep; 25(1):185. PubMed ID: 37773189
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial.
Cohen SB; Pope J; Haraoui B; Irazoque-Palazuelos F; Korkosz M; Diehl A; Rivas JL; Lukic T; Liu S; Stockert L; Iikuni N; Keystone EC
Lancet Rheumatol; 2019 Sep; 1(1):e23-e34. PubMed ID: 38229356
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a
Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M
Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Nash P; Mease PJ; Fleishaker D; Wu J; Coates LC; Behrens F; Gladman DD; Kivitz AJ; Wei JC; Shirinsky I; Menon S; Romero AB; Fallon L; Hsu MA; Wang C; Kanik KS
Lancet Rheumatol; 2021 Jan; 3(1):e28-e39. PubMed ID: 38273637
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
Citera G; Jain R; Irazoque F; Madariaga H; Gruben D; Wang L; Stockert L; Santana K; Ebrahim A; Ponce de Leon D
Rheumatol Ther; 2024 Feb; 11(1):35-50. PubMed ID: 37925660
[TBL] [Abstract][Full Text] [Related]
14. Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity.
Ruyssen-Witrand A; Guernec G; Dupont J; Lapuyade D; Lioté F; Vittecoq O; Degboé Y; Constantin A
Arthritis Res Ther; 2023 Oct; 25(1):207. PubMed ID: 37864239
[TBL] [Abstract][Full Text] [Related]
15. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis.
Reed GW; Gerber RA; Shan Y; Takiya L; Dandreo KJ; Gruben D; Kremer J; Wallenstein G
Rheumatol Ther; 2019 Nov; 6(4):573-86. PubMed ID: 31707603
[TBL] [Abstract][Full Text] [Related]
16. Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study.
Caporali R; Taylor PC; Aletaha D; Sanmartí R; Takeuchi T; Mo D; Haladyj E; Bello N; Zaremba-Pechmann L; Fang Y; Dougados M
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38258434
[TBL] [Abstract][Full Text] [Related]
17. Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4).
Tanaka Y; Takeuchi T; Morita Y; Kato D; Kaneko Y; Terada W
Mod Rheumatol; 2024 Mar; 34(3):453-465. PubMed ID: 37319017
[TBL] [Abstract][Full Text] [Related]
18. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
[TBL] [Abstract][Full Text] [Related]
19. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
Tanaka Y; Atsumi T; Aletaha D; Bartok B; Pechonkina A; Han L; Emoto K; Kano S; Rajendran V; Takeuchi T
Rheumatol Ther; 2023 Feb; 10(1):161-185. PubMed ID: 36327094
[TBL] [Abstract][Full Text] [Related]
20. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
Orbai AM; Mease PJ; Helliwell PS; FitzGerald O; Fleishaker DL; Mundayat R; Young P
BMC Rheumatol; 2022 Sep; 6(1):68. PubMed ID: 36045453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
